GLP-1 MEDICATIONS AND THE LYMPHATIC SYSTEM: WHY THE LYMPH WORLD IS PAYING ATTENTION

Laine Kristin Miller, PTA, LMT, C-MLD, CLT

For years, lymphedema has been framed almost entirely as a mechanical problem: damaged or absent lymph vessels, lymph node removal, radiation scarring, and tissue that simply cannot drain. That "plumbing" model is still true and important–but emerging research around GLP-1 medications is forcing us to widen the lens to include metabolism, insulin resistance, and chronic inflammation as key players in lymphatic health.

This article is not about hyping GLP-1 drugs as a cure. It is about understanding why these medications, designed for diabetes and weight management, are suddenly showing up in conversations about lymphedema risk and lymphatic repair.

Individuals who have arm lymph nodes removed for breast cancer face an increased risk of lymphedema, especially if they are overweight or insulin resistant. This study investigates whether GLP-1 medications can reduce the occurrence of lymphedema in these patients following surgery.
Click the QR code to read this study.

What the GLP-1 / Lymphedema Studies Actually Show

A large breast-cancer cohort: GLP-1 use and lower lymphedema rates

A 2024 retrospective study looked at more than 3,800 breast-cancer patients who had undergone axillary lymph node dissection—one of the highest-risk procedures for developing secondary lymphedema of the arm. Among these patients, a small subgroup was taking GLP-1 receptor agonists (the "Ozempic-like" class of medications) during or after treatment.

When the researchers compared outcomes, they found that:

The overall lymphedema rate in the non-GLP-1 group was high, consistent with what we see clinically after axillary dissection.

In the GLP-1 group, the percentage of patients who developed lymphedema was dramatically lower.

Even after adjusting for factors like BMI, diabetes status, chemotherapy, and radiation, GLP-1 users had a much lower odds of developing lymphedema.

Because this was a retrospective, observational study, it cannot prove that GLP-1 medications caused the lower lymphedema rate. But the signal was strong enough that it has the attention of oncologists, endocrinologists, and lymphatic clinicians. It raises an important question: are GLP-1 drugs doing something protective at the level of lymphatic vessels, or are they simply a marker for patients with better metabolic control and follow-up?

A mechanistic review: from "plumbing problem" to metabolic-vascular condition

Exploring Lymphedema Through a Recent Narrative Review:

A more recent narrative review delves into the mechanisms of lymphedema, placing it within a broader context. The authors compile data from various fields, including basic science, vascular biology, immunology, and clinical observations, to support the following points:

Chronic hyperinsulinemia and insulin resistance can harm lymphatic endothelial cells through several pathways:

- PI3K/AKT disruption
- Oxidative stress
- Advanced glycation end products
- NF-κB-driven inflammation

This metabolic "toxic load" leads to lymphatic leakiness, inadequate pumping, tissue fibrosis, and fat deposition—conditions we clinically observe in both primary and secondary lymphedema.

GLP-1 receptor agonists may mitigate some of these processes by:

- Enhancing insulin sensitivity
- Decreasing inflammation

Supporting the signaling pathways that promote lymphangiogenesis and endothelial repair.

This thought process should also apply to other lymphtatic conditions such as Lipedema, phlebo-lymphedema and obesity related lymphatic issues

Recent studies also highlight early clinical observations, including a case in which breast-cancer–related arm lymphedema improved while the patient was treated with a GLP-1 medication.

Over time, limb volume decreased, lymphatic imaging showed improved function, and the patient was able to reduce or discontinue compression.

Taken together, these publications do not provide definitive evidence or treatment guidelines, but they do offer a biologically plausible explanation for why GLP-1 medications might influence lymphatic outcomes.

How GLP-1 Medications Could Affect Lymphatics

GLP-1 receptor agonists were designed to help regulate blood sugar, but their effects reach far beyond the pancreas. To understand their potential lymphatic impact, it helps to think in two layers: metabolic and vascular/lymphatic.

Metabolic layer: reducing the "background noise" that hurts lymphatics

In many of the patients we see with lymphedema or lipedema, there is a backdrop of metabolic dysfunction: insulin resistance, prediabetes or diabetes, central adiposity, and chronic, low-grade inflammation.

Increased inflammation affects lymphatic function in several significant ways:

1. Elevates circulating insulin and glucose levels.
2. Raises the levels of pro-inflammatory cytokines and adipokines.
3. Promotes fat deposition within and around lymphatic vessels.
4. Induces oxidative stress that damages endothelial cells.

GLP-1 medications have been shown to:

1. Enhance insulin sensitivity and reduce hyperinsulinemia.
2. Suppress appetite and facilitate weight loss.
3. Lower specific inflammatory markers.

By mitigating metabolic disturbances, GLP-1 medications may indirectly foster a more conducive environment for the proper functioning and repair of lymphatic vessels.

In addition, the reduction of inflammation may play a role in reduction in pain, excessive histamine responses, and skin sensitivity, which can lead to a reduction in skin changes, improved lymphatic vessel repair, and improved response and tolerence to treatments such as MLD, compression and exercise..

By calming that metabolic storm, GLP-1s may indirectly create a more favorable environment for lymphatic vessels to function and repair.

This in combination with lifestyle changes, addressing food and chemical sensitivities and addressing other medical comorbidities is the key to a holistic approach in lymphatic care.

GLP-1s show promia in supporting a complete approach to individualized care where the patient is medically managed by their doctor.

Vascular and lymphatic layer: direct effects on the vessel wall



In addition to their metabolic effects, GLP-1 receptors have been found on endothelial cells, including those within lymphatic vessels.

Research indicates that GLP-1 signaling can:

- Enhance PI3K/AKT signaling and VEGF-C/VEGFR-3 activity, which are vital pathways for lymphangiogenesis and lymphatic remodeling.
- Increase nitric oxide production through eNOS, promoting vessel health and ensuring proper contractility of collecting lymphatics.
- Reduce activation of NF-κB and other inflammatory pathways, potentially limiting fibrosis and structural damage.

Preliminary animal studies have demonstrated improved lymphatic pumping and functionality with GLP-1 receptor agonism in models of metabolic disease.

While these are preclinical findings, they support the notion that GLP-1 medications may offer direct lymphatic benefits beyond mere weight loss.

With this kind of emerging data, it's very easy for the conversation to jump ahead of the science. As a lymphatic clinician, it's important to communicate both the promise and the limits.

Understanding GLP-1 Drugs and Lymphedema

- GLP-1 drugs are not an established treatment or cure for lymphedema.
- Currently, there are no **medications* officially approved to specifically prevent or treat lymphedema.
- GLP-1 medications** come with their own set of risks, side effects, and contraindications. As powerful systemic drugs, they should only be prescribed and monitored by qualified medical professionals.
- Not everyone with lymphedema qualifies for these medications, even if future research indicates potential benefits for specific groups.

Implications for the Future

- Metabolic health and lymphatic health are interconnected. Conditions such as insulin resistance, obesity, and chronic inflammation are not merely "background issues"; they actively contribute to lymphatic dysfunction.
- For patients already taking GLP-1 medications for diabetes or obesity, it may be beneficial to closely track lymphatic outcomes over time, including limb volumes, tissue texture, fibrosis, and the frequency of cellulitis.
- Future care models for lymphedema may evolve to be more integrated, with lymphatic therapists working more collaboratively with specialists in endocrinology, obesity medicine, and oncology to address metabolic and vascular risk factors.

If future trials demonstrate positive outcomes, GLP-1 medications (or next-generation agents) might eventually become part of a comprehensive treatment approach that still includes manual therapy, compression, movement, skincare, and, when appropriate, surgical interventions.

How I Am Integrating this as a Lymphatic Clinician

I am not prescribing GLP-1 medications or recommending them as a lymphedema treatment. That is outside my scope and not supported by strong enough evidence—yet.

But this research is changing how I think, assess, and collaborate.

In my practice and teaching, this looks like:

- Placing more emphasis on screening for insulin resistance, metabolic syndrome, and obesity-related risk factors during intake and education.
- Helping patients understand that their lymphatic system and their metabolic health are in constant conversation—what affects one often affects the other.
- Encouraging multidisciplinary collaboration: when a patient is already on a GLP-1 medication prescribed by their physician, continue to track changes in limb volume, tissue quality, symptoms, and infection risk as part of their lymphatic care plan.
- Staying current with the literature so that when patients or providers ask about GLP-1 and lymphedema, I can answer with nuance instead of hype.
- Ultimately this is a conversation for the oatient to have with their doctor.

Questions to Ask and Conversations to Start

For clinicians and patients who are curious about GLP-1 medications and lymphatic health, some useful questions include:

- For patients at high risk of lymphedema (for example, after axillary or groin lymph node dissection), should metabolic risk factors like insulin resistance be addressed more aggressively?
- How can lymphatic therapists and metabolic/obesity medicine providers communicate better when they share patients?
- For individuals already on GLP-1 medications, can we systematically track lymphedema-related outcomes to see whether we observe changes in swelling, tissue feel, or infection rates over time?

What kind of prospective studies do we need next—prevention in high-risk patients, treatment in established lymphedema, or both?

These questions don't have final answers yet, but simply asking them moves our field toward a more integrated, whole-person model of lymphatic care

Early evidence suggests that GLP-1 medications could become a valuable adjunct in recovery for people with lymphatic conditions by targeting both metabolic and vascular drivers of disease.

By improving insulin sensitivity, lowering chronic inflammation, and supporting healthier endothelial and lymphatic signaling pathways, GLP-1 receptor agonists may help create a more favorable environment for lymphatic repair and function.

In breast-cancer survivors after axillary lymph node dissection, GLP-1 use has been associated with a markedly lower incidence of arm lymphedema, and an early case report shows reduced limb volume and improved lymphatic imaging in established lymphedema on GLP-1 therapy.

While these drugs are not yet proven or approved as lymphedema treatments, they point toward a future in which optimizing metabolic health—alongside manual therapy, compression, movement, and skincare—may significantly enhance recovery and long-term outcomes for patients with lymphatic disorders.

This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.

It does not replace individualized medical advice, and it should not be used to make decisions about starting, changing, or stopping any medication, including GLP-1 drugs.

Readers should discuss all questions about lymphedema, lymphatic health, and GLP-1 therapies with their own licensed healthcare providers, who can consider their full medical history and current treatment plan.

References

Brown M, Khavanin N, Coriddi M, et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection for breast cancer. Front Pharmacol. 2024;15:1457363. doi:10.3389/fphar.2024.1457363.

Crowley C, O'Donnell TF, Pusic AL, et al. GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report. J Plast Reconstr Aesthet Surg. 2024;77(5):e7–e12. PMID: 38699640. Available from: [PMCID: PMC11063291].

Waeckerle M, et al. GLP-1R agonism directly improves the pumping capacity of murine collecting lymphatic vessels. bioRxiv. 2025. doi:10.1101/2025.12.26.696603.

Soran A, Ozmen T, McGuire KP, et al. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol. 2016;14(1):2–8.

Shah C, Vicini F, Arthur D, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Ann Surg Oncol. 2012;19(3):864–872.

DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–515.

Ridner SH, Dietrich MS, Stewart BR, Armer JM. Breast cancer-related lymphedema: risk factors in a prospective surveillance model. Cancer. 2020;126(15):3528–3536.

Efficacy of GLP-1 receptor agonists in treating upper and lower extremity lymphedema (ISL stages II–III). ClinicalTrials.gov identifier: NCT07012642.